Table 2.
Demographic and Clinical Profile of PD Suicide Cases and Non‐Suicide Controls
| Variables |
PD Controls (n = 30) |
N* = 30 |
PD Suicide (n = 10) |
N* = 10 | p Value |
|---|---|---|---|---|---|
| Age (years) | 74.48 (+7.16) | 30 | 65.9 (+13.12) | 10 | 0.015 |
| Gender (male) | 14 (47%) | 30 | 7 (70%) | 10 | 0.281 |
| Race (Chinese) | 24 (80%) | 30 | 10 (100%) | 10 | 0.307 |
| Married | 27 (96%) | 28 | 8 (100%) | 8 | 1 |
| Education (years) | 5.23 (+4.33) | 26 | 6.88 (+4.39) | 8 | 0.413 |
| Employed | 1 (4%) | 25 | 2 (25%) | 8 | 0.139 |
| CWI | 4.63 (+1.54) | 30 | 2.6 (+1.43) | 10 | 0.001 |
| Duration of disease (years) | 6.81 (+4.56) | 30 | 6.82 (+4.13) | 10 | 0.842 |
| MMSE | 21.36 (+4.41) | 22 | 25.75 (+3.28) | 8 | 0.012 |
| Hallucinations | 11 (37%) | 30 | 1 (11%) | 9 | 0.228 |
| Depression | 4 (13%) | 30 | 4 (40%) | 10 | 0.089 |
| UPDRS III (motor score) | 41.63 (+17.7) | 30 | 20.83 (+8.28) | 9 | 0.002 |
| Hoehn & Yahr stage | 3.86 (+1.09) | 30 | 2.16 (+0.35) | 9 | 0.000 |
| Motor fluctuation | 11 (37%) | 30 | 6 (67%) | 9 | 0.142 |
| Dyskinesia | 5 (60%) | 30 | 2 (22%) | 9 | 0.653 |
| Levodopa equivalent dose (mg) | 631.65 (+355.46) | 30 | 820.88 (+425.86) | 10 | 0.173 |
| Entacapone | 1 (3%) | 30 | 4 (40%) | 10 | 0.01 |
| Trihexyphenidyl | 2 (6%) | 30 | 2 (20%) | 10 | 0.256 |
| Selegiline | 1 (3%) | 30 | 2 (20%) | 10 | 0.149 |
| Dopamine agonists | 4 (13%) | 30 | 4 (40%) | 10 | 0.089 |
| Antidepressants | 3 (10%) | 30 | 1 (10%) | 10 | 1 |
| Antipsychotics | 4 (13%) | 30 | 0 (0%) | 10 | 0.556 |
Abbreviations: CWI‐ Charlson's Weighted Index, MMSE‐Mini Mental State Examination; N*, valid numbers; UPDRS‐Unified Parkinson Disease Rating Scale.
Note: values are expressed in mean (+standard deviation) or frequency (percentage)